Mayank Bansal is a CFA Charterholder and heads the Equity Research team at Kapitales Research, with over 5 years of experience analysing global equity markets. He leads fundamental, data-driven research combining rigorous financial analysis with macro trends.
Monash IVF’s ASX Sell-Off Puts Its October Rebound to the Test
Source: Kapitales Research
Highlights
Monash IVF expects annual underlying profit to fall well below last year’s result and analyst forecasts.
Australian stimulated IVF cycles fell 3.2% in the September quarter, while Monash IVF’s market share held steady.
The company still targets AU$8–11 million in annual pre-tax savings, with the benefits taking longer to reach earnings.
A softer profit outlook hits shares
Monash IVF Group Limited (ASX: MVF) shares dropped 22.5% to AU$0.585 on 20 November 2026 as investors digested a weaker profit outlook. The fertility provider expects underlying net profit after tax for FY27 to fall well short of both its FY26 result and current analyst forecasts if industry activity fails to pick up in the second half.
Market share holds as IVF activity slows
Australian stimulated IVF cycles fell 3.2% in the September quarter compared to the June quarter, according to the trading update. The company put its rolling 12-month market share at 19.4%, broadly level with June, and reported a 0.5% decline in industry cycles alongside that measure. Monash IVF gained share across most states during the quarter, but fresh competition cut into its position in South Australia. Its smaller international business continued to perform strongly.
Treatment volumes and earnings improved in October and November compared to the first quarter, with the company also seeing gains from its productivity program. Even so, occupancy costs, wages, insurance premiums and some supplier prices rose faster than domestic inflation.
New facilities add costs ahead of growth
The company is reducing headcount, renegotiating supplier terms and curbing discretionary spending. It still aims to save AU$8–11 million a year before tax, but those savings will take longer than planned to flow through to profit. Depreciation and interest expenses are also expected to exceed FY26 levels after investment in new facilities and an increase in debt.
The Brisbane relocation took operations offline for about a month in July. Management expects the new site to settle into a steady operating pace by the end of the December quarter. Western Australia’s additional ultrasound capacity is opening in stages, while Clayton is due to welcome patients in December 2026. At Cremorne, theatre utilisation more than doubled and volumes rose 22% from the June quarter to the September quarter after surgical activity was consolidated there. The move preserved IVF volumes.
Outlook
Monash IVF plans to revisit its outlook at the half-year results. The board said market conditions made it difficult to put a figure on FY27 earnings. By then, investors should have a clearer view of whether the October and November gains persisted, how quickly the new facilities are filling up and how much of the targeted savings has reached the bottom line.
Note- All data presented is based on information available at the time of writing.
Disclaimer for Kapitales Research
The materials provided by Kapitales Research, including articles, news, data, reports, opinions, images, charts, and videos ("Content"), are intended for personal, non-commercial use only. The primary goal of this Content is to educate and inform readers. This Content is not meant to offer financial advice, nor does it include any recommendation or opinion that should be relied upon for making financial decisions. Certain Content on this platform may be sponsored or unsponsored, but it does not serve as a solicitation or endorsement to buy, sell, or hold any securities, nor does it encourage any specific investment activities. Kapitales Research is not authorized to provide investment advice, and we strongly advise users to seek guidance from a qualified financial professional, such as a financial advisor or stockbroker, before making any investment choices. Kapitales Research disclaims all liability for any direct, indirect, incidental, or consequential damages arising from the use of the Content, which is provided without any warranties. The opinions expressed by contributors or guests are their own and do not necessarily reflect the views of Kapitales Research. Media such as images or music used on this platform are either owned by Kapitales Research, sourced through paid subscriptions, or believed to be in the public domain. We have made reasonable efforts to credit sources where appropriate. Kapitales Research does not claim ownership of any third-party media unless explicitly stated otherwise.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.Disclosure: The information mentioned above has been sourced from the company reports and a third-party database, i.e. Koyfin. Investors are advised to use strict stop-loss to protect their investments in case of any unfavorable/uncertain market events.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
We use cookies to help us improve, promote, and protect our services.
By continuing to use this site, we assume you consent to this.
Read our
Privacy Policy
and
Terms & Conditions
Monash IVF’s ASX Sell-Off Puts Its October Rebound to the Test
Highlights
A softer profit outlook hits shares
Monash IVF Group Limited (ASX: MVF) shares dropped 22.5% to AU$0.585 on 20 November 2026 as investors digested a weaker profit outlook. The fertility provider expects underlying net profit after tax for FY27 to fall well short of both its FY26 result and current analyst forecasts if industry activity fails to pick up in the second half.
Market share holds as IVF activity slows
Australian stimulated IVF cycles fell 3.2% in the September quarter compared to the June quarter, according to the trading update. The company put its rolling 12-month market share at 19.4%, broadly level with June, and reported a 0.5% decline in industry cycles alongside that measure. Monash IVF gained share across most states during the quarter, but fresh competition cut into its position in South Australia. Its smaller international business continued to perform strongly.
Treatment volumes and earnings improved in October and November compared to the first quarter, with the company also seeing gains from its productivity program. Even so, occupancy costs, wages, insurance premiums and some supplier prices rose faster than domestic inflation.
New facilities add costs ahead of growth
The company is reducing headcount, renegotiating supplier terms and curbing discretionary spending. It still aims to save AU$8–11 million a year before tax, but those savings will take longer than planned to flow through to profit. Depreciation and interest expenses are also expected to exceed FY26 levels after investment in new facilities and an increase in debt.
The Brisbane relocation took operations offline for about a month in July. Management expects the new site to settle into a steady operating pace by the end of the December quarter. Western Australia’s additional ultrasound capacity is opening in stages, while Clayton is due to welcome patients in December 2026. At Cremorne, theatre utilisation more than doubled and volumes rose 22% from the June quarter to the September quarter after surgical activity was consolidated there. The move preserved IVF volumes.
Outlook
Monash IVF plans to revisit its outlook at the half-year results. The board said market conditions made it difficult to put a figure on FY27 earnings. By then, investors should have a clearer view of whether the October and November gains persisted, how quickly the new facilities are filling up and how much of the targeted savings has reached the bottom line.
Note- All data presented is based on information available at the time of writing.
Disclaimer for Kapitales Research
The materials provided by Kapitales Research, including articles, news, data, reports, opinions, images, charts, and videos ("Content"), are intended for personal, non-commercial use only. The primary goal of this Content is to educate and inform readers. This Content is not meant to offer financial advice, nor does it include any recommendation or opinion that should be relied upon for making financial decisions. Certain Content on this platform may be sponsored or unsponsored, but it does not serve as a solicitation or endorsement to buy, sell, or hold any securities, nor does it encourage any specific investment activities. Kapitales Research is not authorized to provide investment advice, and we strongly advise users to seek guidance from a qualified financial professional, such as a financial advisor or stockbroker, before making any investment choices. Kapitales Research disclaims all liability for any direct, indirect, incidental, or consequential damages arising from the use of the Content, which is provided without any warranties. The opinions expressed by contributors or guests are their own and do not necessarily reflect the views of Kapitales Research. Media such as images or music used on this platform are either owned by Kapitales Research, sourced through paid subscriptions, or believed to be in the public domain. We have made reasonable efforts to credit sources where appropriate. Kapitales Research does not claim ownership of any third-party media unless explicitly stated otherwise.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.Disclosure: The information mentioned above has been sourced from the company reports and a third-party database, i.e. Koyfin. Investors are advised to use strict stop-loss to protect their investments in case of any unfavorable/uncertain market events.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au